Neurocrine Biosciences Inc. Daily Stock Analysis

Daily Stock Analysis, NBIX, Neurocrine Biosciences Inc, priceseries

Neurocrine Biosciences Inc. Daily Stock Analysis
Stock Information
Open
87.36
Close
87.95
High
89.09
Low
87.31
Previous Close
88.19
Daily Price Gain
-0.24
YTD High
92.84
YTD High Date
Mar 2, 2022
YTD Low
71.88
YTD Low Date
Jan 10, 2022
YTD Price Change
-0.52
YTD Gain
-0.59%
52 Week High
108.02
52 Week High Date
Nov 1, 2021
52 Week Low
71.88
52 Week Low Date
Jan 10, 2022
52 Week Price Change
-1.42
52 Week Gain
-1.59%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 30. 2017
53.80
Sep 14. 2017
56.97
10 Trading Days
5.90%
Link
LONG
Sep 27. 2017
58.74
Oct 16. 2017
61.71
13 Trading Days
5.06%
Link
LONG
Dec 20. 2017
71.41
Jan 8. 2018
77.98
11 Trading Days
9.20%
Link
LONG
Jan 19. 2018
80.68
Jan 31. 2018
86.04
8 Trading Days
6.64%
Link
LONG
May 10. 2018
87.83
Jun 22. 2018
102.07
30 Trading Days
16.22%
Link
LONG
Jan 4. 2019
74.71
Jan 25. 2019
85.96
14 Trading Days
15.05%
Link
LONG
Mar 11. 2019
80.02
Mar 27. 2019
85.24
12 Trading Days
6.52%
Link
LONG
Oct 11. 2019
90.33
Dec 9. 2019
114.68
40 Trading Days
26.96%
Link
LONG
May 4. 2020
99.38
May 27. 2020
116.15
16 Trading Days
16.88%
Link
LONG
Jun 16. 2020
118.89
Jun 29. 2020
125.63
9 Trading Days
5.67%
Link
LONG
Jan 6. 2021
97.45
Jan 27. 2021
111.16
14 Trading Days
14.07%
Link
LONG
Jan 28. 2022
76.73
Feb 24. 2022
83.24
18 Trading Days
8.49%
Link
Company Information
Stock Symbol
NBIX
Exchange
NasdaqGS
Company URL
http://www.neurocrine.com
Company Phone
(858) 617-7600
CEO
Kevin Charles Gorman
Headquarters
California
Business Address
12780 EL CAMINO REAL, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0000914475
About

Neurocrine Biosciences, Inc. operates as a product based biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale on January, 1992 and is headquartered in San Diego, CA.

Description

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading